Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDH7
REST API REST API
Homo sapiens
CDH7 is differentially expressed in 142 experiments: 85 organism parts: trigeminal ganglion, cerebellum, ... (83 more);, 96 disease states: normal, glioblastoma, ... (94 more);, 46 cell types 139 cell lines 11 compound treatments and 63 other conditions.
Orthologs F6XHP5_CIOIN (Ciona intestinalis)   cdh7 (Danio rerio)   Cdh7 (Mus musculus)   CDH7 (2 of 2) (Danio rerio)   CDH7 (Bos taurus)   F6RU30_CIOIN (Ciona intestinalis)   F1P1D4_CHICK (Gallus gallus)   Cdh7 (Rattus norvegicus)   cdh7 (Xenopus laevis)   CDH7 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, adherens junction organization, cell-cell adhesion, membrane, homophilic cell adhesion, cell-cell junction organization, cell adhesion, integral to membrane, calcium ion binding, cell junction assembly
InterPro Term Cadherin, Cadherin_cytoplasmic-dom
UniProt Accession Q9ULB5, F5H5X9
Search EB-eye ENSG00000081138
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (13 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-22152, E-GEOD-14464, E-GEOD-19639, ... (20 experiments)

Factor Value U/D Experiments
MCF-10A
2
E-TABM-420, E-GEOD-14990
MCF-7
2
E-GEOD-5823, E-GEOD-19639
MDA468
2
E-MEXP-440, E-MTAB-62
primary culture
2
E-GEOD-2450, E-GEOD-1657
MDAMB175VII
1
E-MTAB-37
WIDR
1
E-MTAB-37
133 more value(s).


Cell type

studied in E-GEOD-18811, E-AFMX-5, E-MTAB-24, E-MTAB-25, E-GEOD-3920, ... (21 experiments)

Factor Value U/D Experiments
testis - germ cell
2
E-AFMX-5, E-TABM-145
not specified
1
E-GEOD-18811
B lymphocyte
1
E-GEOD-6691
BDCA4+ dentritic cell
1
E-TABM-145
immortalized cell culture
1
E-GEOD-14990
SCC
1
E-GEOD-19188
40 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-1577, E-GEOD-20602, E-MTAB-62, ... (25 experiments)

Factor Value U/D Experiments
glioblastoma
2
E-GEOD-4290, E-GEOD-4412
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
chronic myelogenous leukemia
1
E-GEOD-5550
control
1
E-GEOD-20602
neuromuscular pain
1
E-GEOD-7307
90 more value(s).


Compound treatment

studied in E-GEOD-1615, E-MEXP-1269, E-GEOD-5258, E-GEOD-3284, E-MEXP-1335, ... (8 experiments)

Factor Value U/D Experiments
none
2
E-GEOD-1615, E-MEXP-1958
glutamine
2
E-MEXP-941, E-MEXP-1335
valproic acid
1
E-GEOD-1615
troglitazone
1
E-GEOD-5258
placebo
1
E-MEXP-1335
bacterial endotoxin
1
1
E-GEOD-3284
5 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-4667, E-MEXP-958, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-21138, E-GEOD-21887

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-21750, E-TABM-321, E-GEOD-19293 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-1741

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1432, E-MEXP-2069, E-GEOD-19519, ... (16 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-12293, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271

Processing time: 0.549 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM